Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.59 |
| ▸ | PTGDR2 | Q9Y5Y4 | 13/20 | 0.57 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.54 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.45 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.45 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12568856 | 0.91 | NR1H4 (0.49) | NR1H4PTGDR2TBXA2RPTGDRMEN1 | |
| SCHEMBL1652448 | 0.87 | KDM4E (0.57) | PTGDR2TBXA2RPTGDR | |
| SCHEMBL12952844 | 0.87 | PTGDR2 (0.60) | NR1H4PTGDR2TBXA2RPTGDRMEN1 | |
| SCHEMBL1650967 | 0.87 | PTGDR2 (0.71) | NR1H4PTGDR2TBXA2RPTGDRMEN1 | |
| SCHEMBL1654069 | 0.86 | KMT2A (0.52) | PTGDR2TBXA2RPTGDRMEN1KMT2A | |
| SCHEMBL27634916 | 0.86 | NR1H4 (0.46) | NR1H4PTGDR2TBXA2RPTGDRMEN1 | |
| SCHEMBL1652098 | 0.86 | PTGDR2 (0.54) | NR1H4PTGDR2TBXA2RPTGDRMEN1 | |
| SCHEMBL1654146 | 0.86 | PTGDR2 (0.57) | PTGDR2TBXA2RPTGDRMEN1KMT2A | |
| SCHEMBL1008774 | 0.86 | PTGDR2 (0.59) | NR1H4PTGDR2TBXA2RPTGDRMEN1 | |
| SCHEMBL1654021 | 0.86 | PTGDR2 (0.59) | NR1H4PTGDR2TBXA2RPTGDRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960393-B2 | Pyrimidine derivatives useful for the treatment of diseases mediated by CRTH2 | ACTIMIS PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | claimed |
| JP-4671955-B2 | — | — | 2011-04-20 | — | — | JP | claimed |
| US-20100322980-A1 | PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY CRTH2 | GB005, INC. | 2010-12-23 | — | — | US | claimed |
| US-7812160-B2 | Pyrimidine derivatives useful for the treatment of diseases mediated by CRTH2 | ACTIMIS PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | claimed |
| US-20070129355-A1 | G-protein-coupled chemoattractant receptor, expressed on T helper cells antagonists such as [4-(dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)-5-pyrimidinyl]acetic acid;, used for the treatment of allergic diseases, inflammatory diseases, eosinophil- and basophil-related diseases | ACTIMIS PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | US | claimed |
| JP-2006524645-A | — | — | 2006-11-02 | — | — | JP | claimed |
| EP-1633726-A1 | PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY CRTH2 | Actimis Pharmaceuticals, Inc., (US) | 2006-03-15 | — | — | EP | claimed |
| EP-1471057-B1 | Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2 | ACTIMIS PHARMACEUTICALS INC (US) | 2006-01-18 | — | — | EP | claimed |
| WO-2004096777-A1 | PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY CRTH2 | ACTIMIS PHARMACEUTICALS, INC. (US) | 2004-11-11 | — | — | WO | claimed |
| EP-1471057-A1 | Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2 | Bayer HealthCare AG (DE) | 2004-10-27 | — | — | EP | claimed |
| WO-2014079806-A1 | PYRIMIDINE COMPOUNDS FOR TREATING HAIRLOSS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-30 | — | — | WO | disclosed |
| US-20140148470-A1 | PYRIMIDINE COMPOUNDS FOR TREATING HAIRLOSS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-29 | — | — | US | disclosed |
| US-20140148470-A1 | PYRIMIDINE COMPOUNDS FOR TREATING HAIRLOSS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-29 | — | — | US | disclosed |
| US-20120129820-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20120129820-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20070129355-A1 | G-protein-coupled chemoattractant receptor, expressed on T helper cells antagonists such as [4-(dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)-5-pyrimidinyl]acetic acid;, used for the treatment of allergic diseases, inflammatory diseases, eosinophil- and basophil-related diseases | ACTIMIS PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | US | disclosed |
| EP-1633726-A1 | PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY CRTH2 | Actimis Pharmaceuticals, Inc., (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1471057-B1 | Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2 | ACTIMIS PHARMACEUTICALS INC (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004096777-A1 | PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY CRTH2 | ACTIMIS PHARMACEUTICALS, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| EP-1471057-A1 | Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2 | Bayer HealthCare AG (DE) | 2004-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129355-A1 | G-protein-coupled chemoattractant receptor, expressed on T helper cells antagonists such as [4-(dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)-5-pyrimidinyl]acetic acid;, used for the treatment of allergic diseases, inflammatory diseases, eosinophil- and basophil-related diseases | HRH2, HRH1, HRH4 | NR1H4 121/4885PTGDR2 78/4885TBXA2R 48/4885 |
| US-20100322980-A1 | PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY CRTH2 | HRH2, HRH1, CXCR2 | NR1H4 148/4885PTGDR2 73/4885TBXA2R 60/4885 |
| US-20140148470-A1 | PYRIMIDINE COMPOUNDS FOR TREATING HAIRLOSS | TYMS, TYMP, DHFR | NR1H4 1282/4885PTGDR2 1511/4885TBXA2R 945/4885 |
| US-20120129820-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | HRH2, HRH1, HRH4 | NR1H4 6/4885PTGDR2 11/4885TBXA2R 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.